Changchun BCHT Biotechnology Co., Ltd. (SHA: 688276) announced that its Adsorbed Acellular Pertussis (Two‑Component) Diphtheria and Tetanus Combined Vaccine for adolescents and adults has been cleared for clinical trials by the National Medical Products Administration (NMPA).
Product Overview
| Feature | Details |
|---|---|
| Indication | Preventive vaccine for pertussis, diphtheria, and tetanus in individuals ≥ 10 years |
| Target Population | Adolescents and adults (10 + years) |
| Delivery | Injectable, single‑dose immunization |
| Immunological Profile | Induces robust humoral immunity against Bordetella pertussis (two‑component antigens), Corynebacterium diphtheriae toxin, and Clostridium tetani toxin |
The novel formulation is adsorbed, optimizing antigen presentation and enabling a broader protective effect in the adult demographic where pertussis incidence is rising.
Regulatory Milestone
- Approval Status – NMPA granted permission to commence Phase I/II clinical trials.
- Significance – First DTaP vaccine specifically approved for the adult population in China; previously the national immunization schedule focused exclusively on infants.
- Timeline – Clinical evaluation set to begin in early 2026 with anticipated approval for marketing (clinical use) in 2027–2028, contingent on trial outcomes.
Market Context
- Epidemiologic Trend – Global and domestic pertussis outbreaks among adults have surged, prompting many countries to adopt adolescent/adult DTaP boosters every 10 years.
- Health‑system Gap – China lacks a licensed adult booster, creating a public‑health opening for BCHT to capture a new immunization niche.
- Competitive Landscape – BCHT will compete with established infant DTaP manufacturers and foreign brands that have already introduced adult boosters in international markets.
Investor Implications
- Strategic Expansion – Access to a high‑growth indication beyond the infant market widens BCHT’s revenue base.
- Pipeline Value – The regulatory clearance accelerates the vaccine’s development schedule, potentially shortening time‑to‑market by 1–2 years compared with traditional pathways.
- Future Potential – Successful trials could lead to national licensing and inclusion in the routine adult immunization program, positioning BCHT as a leader in adult pertussis immunity in China.
Forward‑Looking Statements
The viewpoints expressed are forward‑looking and are subject to risks and uncertainties. Actual results may differ materially from those described herein.-Fineline Info & Tech
